Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27209994 | 1.00 | LMNA (0.51) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL10902326 | 0.94 | LMNA (0.49) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL23374594 | 0.83 | LMNA (0.46) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL4570867 | 0.83 | LMNA (0.46) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL23374635 | 0.83 | LMNA (0.46) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL17828063 | 0.81 | LMNA (0.46) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL3661871 | 0.80 | ALDH1A1 (0.45) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL24322671 | 0.79 | KDM4E (0.54) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL23183278 | 0.78 | LMNA (0.43) | LMNAMEN1KMT2ATSHRKDM4E | |
| SCHEMBL9801279 | 0.77 | TDP1 (0.43) | LMNAMEN1KMT2ATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| CN-110621711-A | Photocurable composition containing fluorine-based polymer | 捷恩智株式会社 | 2019-12-27 | — | — | CN | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | LMNA 1220/4885MEN1 130/4885KMT2A 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.